Secondary Hyperparathyroidism (SHPT)

Secondary Hyperparathyroidism (SHPT) is the indication for 7 drugs in DrugBank. It is covered by 15 curated, structured indications.

Also known as: Secondary Hyperparathyroidism · secondary hyperparathyroidism (HPT)
Classified under: Endocrine System Diseases
Nutritional and Metabolic Diseases
Urogenital Diseases
Indicated drugs: Alfacalcidol
Calcifediol
Calcitriol
Cinacalcet
Doxercalciferol
Etelcalcetide
Paricalcitol

Resolves to

Vocabularies

MeSHT020912SNOMED CT91478007MedDRA10020708UMLSC0020503

What you can answer from here — as of October 24, 2026

7Indicated drugsWith each drug's targets and mechanism

Listed above

15Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

138Clinical trialsPhase, status and sponsor resolved per trial

3Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Secondary Hyperparathyroidism (SHPT) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.